Status: Recruiting
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
Participants needed: 70
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kelonia Therapeutics, Inc.Updated: Apr 24, 2026Locations: 7
Eligibility criteria
Participants must have relapsed and refractory multiple myeloma (RRMM) with meas... [+3]
Participants must not have known central nervous system (CNS) involvement with m... [+3]